PFO
VIR icon

Pathstone Family Office’s Vir Biotechnology VIR Stock Holding History

Pathstone Family Office’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30
Closed -$1K – 1001
2020
Q2 		$1K Buy
+30
New +$1.01K ﹤0.01% 690

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pathstone Family Office's VIR Position: Q3 2020 in Review

Pathstone Family Office sold out of Vir Biotechnology (VIR) in Q3 2020, closing a stake of 30 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in VIR in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 119 funds tracked by Wall St. Rank hold VIR as of Q3 2020.

  • Pathstone Family Office reported no remaining Vir Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 30 Vir Biotechnology shares in Q3 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in Vir Biotechnology in Q2 2020 and held it in 1 quarter.
  • Pathstone Family Office's Vir Biotechnology position peaked at $1K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.